APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vasculitis Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Vasculitis Drug Industry Growth and Trends Forecast to 2032

19 December 202593 pages

Choose your research edition.

Industry ResearchVasculitis Drug Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Vasculitis Drug Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Vasculitis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vasculitis Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Vasculitis Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Vasculitis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Vasculitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Vasculitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vasculitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vasculitis Drug include Shanghaihuangxiang Lantian Pharmaceutical, Merck, Huzhou Konch Pharmaceutical, Hubei Biocause Pharmaceutical, Hainan Pharmaceutical Factory, Bayer, Sino-US Zibo Xinhua-Perrigo Pharmaceutical, Farmalider and CSPC Ouyi Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Vasculitis Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Vasculitis Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Vasculitis Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Vasculitis Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Vasculitis Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Vasculitis Drug Market by Company

Shanghaihuangxiang Lantian Pharmaceutical

Merck

Huzhou Konch Pharmaceutical

Hubei Biocause Pharmaceutical

Hainan Pharmaceutical Factory

Bayer

Sino-US Zibo Xinhua-Perrigo Pharmaceutical

Farmalider

CSPC Ouyi Pharmaceutical

Vasculitis Drug Segment by Type

CCX-168

Blisibimod

Gevokizumab

Rituximab Biosimilar

Others

Vasculitis Drug Segment by Application

Thrombotic Vasculitis

Granulomatous Vasculitis

Lymphocytic Vasculitis

Polyarteritis Nodosa

Others

Vasculitis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vasculitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vasculitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vasculitis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vasculitis Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Vasculitis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of CCX-168 Table 2. Major Company of Blisibimod Table 3. Major Company of Gevokizumab Table 4. Major Company of Rituximab Biosimilar Table 5. Major Company of Others Table 6. Global Vasculitis Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Vasculitis Drug Sales by Type (2021-2026) & (K Units) Table 8. Global Vasculitis Drug Sales Market Share in Volume by Type (2021-2026) Table 9. Global Vasculitis Drug Sales by Type (2021-2026) & (US$ Million) Table 10. Global Vasculitis Drug Sales Market Share in Value by Type (2021-2026) Table 11. Global Vasculitis Drug Price by Type (2021-2026) & (US$/Unit) Table 12. Global Vasculitis Drug Sales by Type (2027-2032) & (K Units) Table 13. Global Vasculitis Drug Sales Market Share in Volume by Type (2027-2032) Table 14. Global Vasculitis Drug Sales by Type (2027-2032) & (US$ Million) Table 15. Global Vasculitis Drug Sales Market Share in Value by Type (2027-2032) Table 16. Global Vasculitis Drug Price by Type (2027-2032) & (US$/Unit) Table 17. North America Vasculitis Drug Sales by Type (2021-2026) & (K Units) Table 18. North America Vasculitis Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Vasculitis Drug Sales by Type (2021-2026) & (K Units) Table 20. Europe Vasculitis Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Vasculitis Drug Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Vasculitis Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Vasculitis Drug Sales by Type (2021-2026) & (K Units) Table 24. Latin America Vasculitis Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Vasculitis Drug Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Vasculitis Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Vasculitis Drug Industry Trends Table 28. Vasculitis Drug Industry Drivers Table 29. Vasculitis Drug Industry Opportunities and Challenges Table 30. Vasculitis Drug Industry Restraints Table 31. Global Vasculitis Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Vasculitis Drug Revenue Market Share by Company (2021-2026) Table 33. Global Vasculitis Drug Sales by Company (2021-2026) & (K Units) Table 34. Global Vasculitis Drug Sales Share by Company (2021-2026) Table 35. Global Vasculitis Drug Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Vasculitis Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Vasculitis Drug Major Company Production Sites and Headquarters Table 38. Global Vasculitis Drug Company, Product Type & Application Table 39. Global Vasculitis Drug Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Vasculitis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Vasculitis Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Vasculitis Drug Sales by Region (2021-2026) & (K Units) Table 44. Global Vasculitis Drug Sales Market Share in Volume by Region (2021-2026) Table 45. Global Vasculitis Drug Sales by Region (2021-2026) & (US$ Million) Table 46. Global Vasculitis Drug Sales Market Share in Value by Region (2021-2026) Table 47. Global Vasculitis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Vasculitis Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Vasculitis Drug Sales Market Share in Volume by Region (2027-2032) Table 50. Global Vasculitis Drug Sales by Region (2027-2032) & (US$ Million) Table 51. Global Vasculitis Drug Sales Market Share in Value by Region (2027-2032) Table 52. Global Vasculitis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Vasculitis Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Vasculitis Drug Sales by Application (2021-2026) & (K Units) Table 55. Global Vasculitis Drug Sales Market Share in Volume by Application (2021-2026) Table 56. Global Vasculitis Drug Sales by Application (2021-2026) & (US$ Million) Table 57. Global Vasculitis Drug Sales Market Share in Value by Application (2021-2026) Table 58. Global Vasculitis Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Vasculitis Drug Sales by Application (2027-2032) & (K Units) Table 60. Global Vasculitis Drug Sales Market Share in Volume by Application (2027-2032) Table 61. Global Vasculitis Drug Sales by Application (2027-2032) & (US$ Million) Table 62. Global Vasculitis Drug Sales Market Share in Value by Application (2027-2032) Table 63. Global Vasculitis Drug Price by Application (2027-2032) & (US$/Unit) Table 64. North America Vasculitis Drug Sales by Application (2021-2026) & (K Units) Table 65. North America Vasculitis Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Vasculitis Drug Sales by Application (2021-2026) & (K Units) Table 67. Europe Vasculitis Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Vasculitis Drug Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Vasculitis Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Vasculitis Drug Sales by Application (2021-2026) & (K Units) Table 71. Latin America Vasculitis Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Vasculitis Drug Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Vasculitis Drug Sales by Application (2021-2026) & (US$ Million) Table 74. Shanghaihuangxiang Lantian Pharmaceutical Company Information Table 75. Shanghaihuangxiang Lantian Pharmaceutical Business Overview Table 76. Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Product Portfolio Table 78. Shanghaihuangxiang Lantian Pharmaceutical Recent Development Table 79. Merck Company Information Table 80. Merck Business Overview Table 81. Merck Vasculitis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Merck Vasculitis Drug Product Portfolio Table 83. Merck Recent Development Table 84. Huzhou Konch Pharmaceutical Company Information Table 85. Huzhou Konch Pharmaceutical Business Overview Table 86. Huzhou Konch Pharmaceutical Vasculitis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Huzhou Konch Pharmaceutical Vasculitis Drug Product Portfolio Table 88. Huzhou Konch Pharmaceutical Recent Development Table 89. Hubei Biocause Pharmaceutical Company Information Table 90. Hubei Biocause Pharmaceutical Business Overview Table 91. Hubei Biocause Pharmaceutical Vasculitis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Hubei Biocause Pharmaceutical Vasculitis Drug Product Portfolio Table 93. Hubei Biocause Pharmaceutical Recent Development Table 94. Hainan Pharmaceutical Factory Company Information Table 95. Hainan Pharmaceutical Factory Business Overview Table 96. Hainan Pharmaceutical Factory Vasculitis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Hainan Pharmaceutical Factory Vasculitis Drug Product Portfolio Table 98. Hainan Pharmaceutical Factory Recent Development Table 99. Bayer Company Information Table 100. Bayer Business Overview Table 101. Bayer Vasculitis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Bayer Vasculitis Drug Product Portfolio Table 103. Bayer Recent Development Table 104. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Company Information Table 105. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Business Overview Table 106. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Product Portfolio Table 108. Sino-US Zibo Xinhua-Perrigo Pharmaceutical Recent Development Table 109. Farmalider Company Information Table 110. Farmalider Business Overview Table 111. Farmalider Vasculitis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Farmalider Vasculitis Drug Product Portfolio Table 113. Farmalider Recent Development Table 114. CSPC Ouyi Pharmaceutical Company Information Table 115. CSPC Ouyi Pharmaceutical Business Overview Table 116. CSPC Ouyi Pharmaceutical Vasculitis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. CSPC Ouyi Pharmaceutical Vasculitis Drug Product Portfolio Table 118. CSPC Ouyi Pharmaceutical Recent Development Table 119. North America Vasculitis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 120. North America Vasculitis Drug Sales by Country (2021-2026) & (K Units) Table 121. North America Vasculitis Drug Sales Market Share by Country (2021-2026) Table 122. North America Vasculitis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 123. North America Vasculitis Drug Sales Market Share Forecast by Country (2027-2032) Table 124. North America Vasculitis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 125. North America Vasculitis Drug Market Size by Country (2021-2026) & (US$ Million) Table 126. North America Vasculitis Drug Market Share by Country (2021-2026) Table 127. North America Vasculitis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 128. North America Vasculitis Drug Market Share Forecast by Country (2027-2032) Table 129. Europe Vasculitis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 130. Europe Vasculitis Drug Sales by Country (2021-2026) & (K Units) Table 131. Europe Vasculitis Drug Sales Market Share by Country (2021-2026) Table 132. Europe Vasculitis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 133. Europe Vasculitis Drug Sales Market Share Forecast by Country (2027-2032) Table 134. Europe Vasculitis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 135. Europe Vasculitis Drug Market Size by Country (2021-2026) & (US$ Million) Table 136. Europe Vasculitis Drug Market Share by Country (2021-2026) Table 137. Europe Vasculitis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 138. Europe Vasculitis Drug Market Share Forecast by Country (2027-2032) Table 139. Asia-Pacific Vasculitis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 140. Asia-Pacific Vasculitis Drug Sales by Country (2021-2026) & (K Units) Table 141. Asia-Pacific Vasculitis Drug Sales Market Share by Country (2021-2026) Table 142. Asia-Pacific Vasculitis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 143. Asia-Pacific Vasculitis Drug Sales Market Share Forecast by Country (2027-2032) Table 144. Asia-Pacific Vasculitis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 145. Asia-Pacific Vasculitis Drug Market Size by Country (2021-2026) & (US$ Million) Table 146. Asia-Pacific Vasculitis Drug Market Share by Country (2021-2026) Table 147. Asia-Pacific Vasculitis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 148. Asia-Pacific Vasculitis Drug Market Share Forecast by Country (2027-2032) Table 149. Latin America Vasculitis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 150. Latin America Vasculitis Drug Sales by Country (2021-2026) & (K Units) Table 151. Latin America Vasculitis Drug Sales Market Share by Country (2021-2026) Table 152. Latin America Vasculitis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 153. Latin America Vasculitis Drug Sales Market Share Forecast by Country (2027-2032) Table 154. Latin America Vasculitis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 155. Latin America Vasculitis Drug Market Size by Country (2021-2026) & (US$ Million) Table 156. Latin America Vasculitis Drug Market Share by Country (2021-2026) Table 157. Latin America Vasculitis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 158. Latin America Vasculitis Drug Market Share Forecast by Country (2027-2032) Table 159. Middle East and Africa Vasculitis Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 160. Middle East and Africa Vasculitis Drug Sales by Country (2021-2026) & (K Units) Table 161. Middle East and Africa Vasculitis Drug Sales Market Share by Country (2021-2026) Table 162. Middle East and Africa Vasculitis Drug Sales Forecast by Country (2027-2032) & (K Units) Table 163. Middle East and Africa Vasculitis Drug Sales Market Share Forecast by Country (2027-2032) Table 164. Middle East and Africa Vasculitis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 165. Middle East and Africa Vasculitis Drug Market Size by Country (2021-2026) & (US$ Million) Table 166. Middle East and Africa Vasculitis Drug Market Share by Country (2021-2026) Table 167. Middle East and Africa Vasculitis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 168. Middle East and Africa Vasculitis Drug Market Share Forecast by Country (2027-2032) Table 169. Key Raw Materials Table 170. Raw Materials Key Suppliers Table 171. Vasculitis Drug Distributors List Table 172. Vasculitis Drug Customers List Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources Table 176. Primary Sources List of Figures Figure 1. Vasculitis Drug Image Figure 2. Global Vasculitis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vasculitis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Vasculitis Drug Sales (2021-2032) & (K Units) Figure 5. CCX-168 Image Figure 6. Global CCX-168 Sales YoY Growth (2021-2032) & (K Units) Figure 7. Blisibimod Image Figure 8. Global Blisibimod Sales YoY Growth (2021-2032) & (K Units) Figure 9. Gevokizumab Image Figure 10. Global Gevokizumab Sales YoY Growth (2021-2032) & (K Units) Figure 11. Rituximab Biosimilar Image Figure 12. Global Rituximab Biosimilar Sales YoY Growth (2021-2032) & (K Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Vasculitis Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Vasculitis Drug Market Share by Type 2025 VS 2032 Figure 17. North America Vasculitis Drug Sales Market Share in Volume by Type in 2025 Figure 18. North America Vasculitis Drug Sales Market Share in Value by Type in 2025 Figure 19. Europe Vasculitis Drug Sales Market Share in Volume by Type in 2025 Figure 20. Europe Vasculitis Drug Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Vasculitis Drug Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Vasculitis Drug Sales Market Share in Value by Type in 2025 Figure 23. Latin America Vasculitis Drug Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Vasculitis Drug Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Vasculitis Drug Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Vasculitis Drug Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Vasculitis Drug Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Thrombotic Vasculitis Image Figure 30. Global Thrombotic Vasculitis Sales YoY Growth (2021-2032) & (K Units) Figure 31. Granulomatous Vasculitis Image Figure 32. Global Granulomatous Vasculitis Sales YoY Growth (2021-2032) & (K Units) Figure 33. Lymphocytic Vasculitis Image Figure 34. Global Lymphocytic Vasculitis Sales YoY Growth (2021-2032) & (K Units) Figure 35. Polyarteritis Nodosa Image Figure 36. Global Polyarteritis Nodosa Sales YoY Growth (2021-2032) & (K Units) Figure 37. Others Image Figure 38. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 39. Global Vasculitis Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Vasculitis Drug Market Share by Application 2025 VS 2032 Figure 41. North America Vasculitis Drug Sales Market Share in Volume by Application in 2025 Figure 42. North America Vasculitis Drug Sales Market Share in Value by Application in 2025 Figure 43. Europe Vasculitis Drug Sales Market Share in Volume by Application in 2025 Figure 44. Europe Vasculitis Drug Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific Vasculitis Drug Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific Vasculitis Drug Sales Market Share in Value by Application in 2025 Figure 47. Latin America Vasculitis Drug Sales Market Share in Volume by Application in 2025 Figure 48. Latin America Vasculitis Drug Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa Vasculitis Drug Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa Vasculitis Drug Sales Market Share in Value by Application in 2025 Figure 51. North America Vasculitis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. North America Vasculitis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America Vasculitis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America Vasculitis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Vasculitis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Europe Vasculitis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Vasculitis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Vasculitis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Vasculitis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Asia-Pacific Vasculitis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Vasculitis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific Vasculitis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Vasculitis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Latin America Vasculitis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Vasculitis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America Vasculitis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Vasculitis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 68. Middle East and Africa Vasculitis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Vasculitis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa Vasculitis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Vasculitis Drug Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. Vasculitis Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • CCX-168
  • Blisibimod
  • Gevokizumab
  • Rituximab Biosimilar
  • Others
Applications
  • Thrombotic Vasculitis
  • Granulomatous Vasculitis
  • Lymphocytic Vasculitis
  • Polyarteritis Nodosa
  • Others
Companies covered
  • Shanghaihuangxiang Lantian Pharmaceutical
  • Merck
  • Huzhou Konch Pharmaceutical
  • Hubei Biocause Pharmaceutical
  • Hainan Pharmaceutical Factory
  • Bayer
  • Sino-US Zibo Xinhua-Perrigo Pharmaceutical
  • Farmalider
  • CSPC Ouyi Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vasculitis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Vasculitis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Vasculitis Drug Market by Type
  6. 1.3.1 CCX-168
  7. 1.3.2 Blisibimod
  8. 1.3.3 Gevokizumab
  9. 1.3.4 Rituximab Biosimilar
  10. 1.3.5 Others
  11. 1.4 Global Vasculitis Drug Market Size by Type
  12. 1.4.1 Global Vasculitis Drug Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Vasculitis Drug Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Vasculitis Drug Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Vasculitis Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Vasculitis Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Vasculitis Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Vasculitis Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Vasculitis Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Vasculitis Drug Industry Trends
  2. 2.2 Vasculitis Drug Industry Drivers
  3. 2.3 Vasculitis Drug Industry Opportunities and Challenges
  4. 2.4 Vasculitis Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Vasculitis Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Vasculitis Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Vasculitis Drug Price (2021-2026)
  4. 3.4 Global Vasculitis Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vasculitis Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Vasculitis Drug Company, Product Type & Application
  7. 3.7 Global Vasculitis Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vasculitis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vasculitis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vasculitis Drug Tier 1, Tier 2, and Tier 3
4 Vasculitis Drug Regional Status and Outlook
  1. 4.1 Global Vasculitis Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Vasculitis Drug Historic Market Size by Region
  3. 4.2.1 Global Vasculitis Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Vasculitis Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Vasculitis Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Vasculitis Drug Forecasted Market Size by Region
  7. 4.3.1 Global Vasculitis Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Vasculitis Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Vasculitis Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Vasculitis Drug by Application
  1. 5.1 Vasculitis Drug Market by Application
  2. 5.1.1 Thrombotic Vasculitis
  3. 5.1.2 Granulomatous Vasculitis
  4. 5.1.3 Lymphocytic Vasculitis
  5. 5.1.4 Polyarteritis Nodosa
  6. 5.1.5 Others
  7. 5.2 Global Vasculitis Drug Market Size by Application
  8. 5.2.1 Global Vasculitis Drug Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Vasculitis Drug Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Vasculitis Drug Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Vasculitis Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Vasculitis Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Vasculitis Drug Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Vasculitis Drug Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Vasculitis Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Shanghaihuangxiang Lantian Pharmaceutical
  2. 6.1.1 Shanghaihuangxiang Lantian Pharmaceutical Company Information
  3. 6.1.2 Shanghaihuangxiang Lantian Pharmaceutical Business Overview
  4. 6.1.3 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Product Portfolio
  6. 6.1.5 Shanghaihuangxiang Lantian Pharmaceutical Recent Developments
  7. 6.2 Merck
  8. 6.2.1 Merck Company Information
  9. 6.2.2 Merck Business Overview
  10. 6.2.3 Merck Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Merck Vasculitis Drug Product Portfolio
  12. 6.2.5 Merck Recent Developments
  13. 6.3 Huzhou Konch Pharmaceutical
  14. 6.3.1 Huzhou Konch Pharmaceutical Company Information
  15. 6.3.2 Huzhou Konch Pharmaceutical Business Overview
  16. 6.3.3 Huzhou Konch Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Huzhou Konch Pharmaceutical Vasculitis Drug Product Portfolio
  18. 6.3.5 Huzhou Konch Pharmaceutical Recent Developments
  19. 6.4 Hubei Biocause Pharmaceutical
  20. 6.4.1 Hubei Biocause Pharmaceutical Company Information
  21. 6.4.2 Hubei Biocause Pharmaceutical Business Overview
  22. 6.4.3 Hubei Biocause Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Hubei Biocause Pharmaceutical Vasculitis Drug Product Portfolio
  24. 6.4.5 Hubei Biocause Pharmaceutical Recent Developments
  25. 6.5 Hainan Pharmaceutical Factory
  26. 6.5.1 Hainan Pharmaceutical Factory Company Information
  27. 6.5.2 Hainan Pharmaceutical Factory Business Overview
  28. 6.5.3 Hainan Pharmaceutical Factory Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Hainan Pharmaceutical Factory Vasculitis Drug Product Portfolio
  30. 6.5.5 Hainan Pharmaceutical Factory Recent Developments
  31. 6.6 Bayer
  32. 6.6.1 Bayer Company Information
  33. 6.6.2 Bayer Business Overview
  34. 6.6.3 Bayer Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Bayer Vasculitis Drug Product Portfolio
  36. 6.6.5 Bayer Recent Developments
  37. 6.7 Sino-US Zibo Xinhua-Perrigo Pharmaceutical
  38. 6.7.1 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Company Information
  39. 6.7.2 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Business Overview
  40. 6.7.3 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Product Portfolio
  42. 6.7.5 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Recent Developments
  43. 6.8 Farmalider
  44. 6.8.1 Farmalider Company Information
  45. 6.8.2 Farmalider Business Overview
  46. 6.8.3 Farmalider Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Farmalider Vasculitis Drug Product Portfolio
  48. 6.8.5 Farmalider Recent Developments
  49. 6.9 CSPC Ouyi Pharmaceutical
  50. 6.9.1 CSPC Ouyi Pharmaceutical Company Information
  51. 6.9.2 CSPC Ouyi Pharmaceutical Business Overview
  52. 6.9.3 CSPC Ouyi Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 CSPC Ouyi Pharmaceutical Vasculitis Drug Product Portfolio
  54. 6.9.5 CSPC Ouyi Pharmaceutical Recent Developments
7 North America by Country
  1. 7.1 North America Vasculitis Drug Sales by Country
  2. 7.1.1 North America Vasculitis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Vasculitis Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Vasculitis Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Vasculitis Drug Market Size by Country
  6. 7.2.1 North America Vasculitis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Vasculitis Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Vasculitis Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Vasculitis Drug Sales by Country
  2. 8.1.1 Europe Vasculitis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Vasculitis Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Vasculitis Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Vasculitis Drug Market Size by Country
  6. 8.2.1 Europe Vasculitis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Vasculitis Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Vasculitis Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Vasculitis Drug Sales by Country
  2. 9.1.1 Asia-Pacific Vasculitis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Vasculitis Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Vasculitis Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Vasculitis Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Vasculitis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Vasculitis Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Vasculitis Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Vasculitis Drug Sales by Country
  2. 10.1.1 South America Vasculitis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Vasculitis Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Vasculitis Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Vasculitis Drug Market Size by Country
  6. 10.2.1 South America Vasculitis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Vasculitis Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Vasculitis Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Vasculitis Drug Sales by Country
  2. 11.1.1 Middle East and Africa Vasculitis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Vasculitis Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Vasculitis Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Vasculitis Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Vasculitis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Vasculitis Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Vasculitis Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Vasculitis Drug Value Chain Analysis
  2. 12.1.1 Vasculitis Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Vasculitis Drug Production Mode & Process
  7. 12.2 Vasculitis Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Vasculitis Drug Distributors
  10. 12.2.3 Vasculitis Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst